Incretins today: multiple effects and therapeutic potential

Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are the incretin hormones initially discovered in the 1960s. GIP and GLP-1 have gained great scientific interest due to their properties in increasing insulin secretion and lowering blood glucose levels. The study of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oksana V. Tsygankova, Varvara V. Veretyuk, Alexander S. Ametov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2019
Materias:	incretins gastric inhibitory polypeptide glucagon-like peptide 1 intestinal hormones glucagon Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/0efa42080d074bf2b56cb951138cb234
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0efa42080d074bf2b56cb951138cb234
record_format	dspace
spelling	oai:doaj.org-article:0efa42080d074bf2b56cb951138cb2342021-11-14T09:00:22ZIncretins today: multiple effects and therapeutic potential2072-03512072-037810.14341/DM9841https://doaj.org/article/0efa42080d074bf2b56cb951138cb2342019-03-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9841https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are the incretin hormones initially discovered in the 1960s. GIP and GLP-1 have gained great scientific interest due to their properties in increasing insulin secretion and lowering blood glucose levels. The study of these incretin hormones has progressed substantially in recent decades, in that their systemic effects has begun to be actively discussed. In particular, incretins are involved in the pathogenesis of obesity and non-alcoholic fatty liver disease. Moreover, incretins are able to improve cognitive function, suppress the formation of β-amyloid plaques and provide an oncoprotective effect. Recent data show promising oncoprotective effect of GLP-1 agonists on prostate and breast cancer. This review provides systematisation of recent data on the role and mechanisms of action of incretin hormones on carbohydrate metabolism, as well as effects not related to glucose homeostasis, which contributes to a better understanding of potential vectors for the development of incretinotropic therapy. In addition, this review offers insight into pathogenic prerequisites and highlights the current issues in creating innovative polyagonists for treatment of type 2 diabetes mellitus.Oksana V. TsygankovaVarvara V. VeretyukAlexander S. AmetovEndocrinology Research Centrearticleincretinsgastric inhibitory polypeptideglucagon-like peptide 1intestinal hormonesglucagonNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 1, Pp 70-78 (2019)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	incretins gastric inhibitory polypeptide glucagon-like peptide 1 intestinal hormones glucagon Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	incretins gastric inhibitory polypeptide glucagon-like peptide 1 intestinal hormones glucagon Nutritional diseases. Deficiency diseases RC620-627 Oksana V. Tsygankova Varvara V. Veretyuk Alexander S. Ametov Incretins today: multiple effects and therapeutic potential
description	Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are the incretin hormones initially discovered in the 1960s. GIP and GLP-1 have gained great scientific interest due to their properties in increasing insulin secretion and lowering blood glucose levels. The study of these incretin hormones has progressed substantially in recent decades, in that their systemic effects has begun to be actively discussed. In particular, incretins are involved in the pathogenesis of obesity and non-alcoholic fatty liver disease. Moreover, incretins are able to improve cognitive function, suppress the formation of β-amyloid plaques and provide an oncoprotective effect. Recent data show promising oncoprotective effect of GLP-1 agonists on prostate and breast cancer. This review provides systematisation of recent data on the role and mechanisms of action of incretin hormones on carbohydrate metabolism, as well as effects not related to glucose homeostasis, which contributes to a better understanding of potential vectors for the development of incretinotropic therapy. In addition, this review offers insight into pathogenic prerequisites and highlights the current issues in creating innovative polyagonists for treatment of type 2 diabetes mellitus.
format	article
author	Oksana V. Tsygankova Varvara V. Veretyuk Alexander S. Ametov
author_facet	Oksana V. Tsygankova Varvara V. Veretyuk Alexander S. Ametov
author_sort	Oksana V. Tsygankova
title	Incretins today: multiple effects and therapeutic potential
title_short	Incretins today: multiple effects and therapeutic potential
title_full	Incretins today: multiple effects and therapeutic potential
title_fullStr	Incretins today: multiple effects and therapeutic potential
title_full_unstemmed	Incretins today: multiple effects and therapeutic potential
title_sort	incretins today: multiple effects and therapeutic potential
publisher	Endocrinology Research Centre
publishDate	2019
url	https://doaj.org/article/0efa42080d074bf2b56cb951138cb234
work_keys_str_mv	AT oksanavtsygankova incretinstodaymultipleeffectsandtherapeuticpotential AT varvaravveretyuk incretinstodaymultipleeffectsandtherapeuticpotential AT alexandersametov incretinstodaymultipleeffectsandtherapeuticpotential
_version_	1718429509361860608

Incretins today: multiple effects and therapeutic potential

Ejemplares similares